Merck & Co's Keytruda Disappoints In Small-Cell Lung Cancer
Triple-Negative Breast Cancer The Next Big Therapeutic Opportunity?
In top-line final Phase III results from KEYNOTE-604, Keytruda improves PFS but not OS when combined with chemotherapy for the first-line treatment of small-cell lung cancer.
You may also be interested in...
Roche’s Tecentriq has been rejected by health technology assessment body NICE for use in small-cell lung cancer on the National Health Service. The move follows an earlier knockback for the drug in PD L1-positive triple-negative breast cancer.
In addition to Opdivo, three other PD-1/L1 inhibitors are in late-stage development for a high-unmet need disease, including Roche's Tecentriq, which will be filed as soon as possible.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.